Prediction of Resistance and Sensitivity to HER2 Targeted Therapy in the Neoadjuvant Setting
Demographics (2)
- COLLECTION_AGE - Age sample was collected (phv00530609.v2.p1)
- SEX - Biological sex (phv00530597.v1.p1)
Disease Events (5)
- AFFECTION_STATUS - Case control status of the subject for breast cancer; all subjects are breast cancer patients. (phv00530603.v1.p1)
- HR_STATUS - Hormone receptor status (phv00530923.v1.p1)
- PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00530611.v2.p1)
- RNASEQ_SUBTYPE - Intrinsic subtype obtained from RNAseq data (phv00530928.v2.p1)
- STAGE - Overall stage (phv00530922.v1.p1)
Race and Ethnicity (1)
- RACE - Self-reported race (phv00530604.v2.p1)
Reproductive Health (1)
- MENO_STATUS - Menopause status (phv00530924.v1.p1)
Other (17)
- ANALYTE_TYPE - Analyte Type (phv00530607.v2.p1)
- BODY_SITE - Body site where sample was collected (phv00530606.v2.p1)
- CONSENT - Consent group as determined by DAC (phv00530596.v1.p1)
- EFS_STAT - Event-free survival status (event is either death by any cause or recurrence - local or distant) (phv00530927.v1.p1)
- EFS_TIME - Time to first event in years (event is either death by any cause or recurrence - local or distant) (phv00530926.v2.p1)
- GEO_ACCESSION - GEO accession ID (phv00530601.v2.p1)
- IS_TUMOR - Tumor status (phv00530608.v2.p1)
- PCR_BREAST - Pathologic complete response in breast (phv00530925.v1.p1)
- PRIMARY_METASTATIC_TUMOR - Primary tumor, metastasis, or transformed cell line (phv00530610.v2.p1)
- SAMPLE_ID - Sample ID (phv00530605.v2.p1)
- SAMPLE_ID - Sample ID (phv00530599.v2.p1)
- SAMPLE_ID - Sample ID (phv00530600.v2.p1)
- SUBJECT_ID - Subject ID (phv00530602.v1.p1)
- SUBJECT_ID - Subject ID (phv00530595.v1.p1)
- SUBJECT_ID - Subject ID (phv00530598.v2.p1)
- TUMOR_TREATMENT - Treatment status of participant at time of tumor collection (phv00530612.v2.p1)
- TX_ARM - Treatment arm of participant (phv00530921.v1.p1)